Geovax Labs Inc (GOVX)
$2.21
+0.09
(+4.25%)▲
Live
Performance
- $2.11$2.37$2.21
4.52%
Downside
Day's Volatility :10.97%
Upside
6.75%
- $1.09$11.18$2.21
50.67%
Downside
52 Weeks Volatility :90.25%
Upside
80.23%
Returns
| Period | Geovax Labs Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -20.6% | 3.6% | 0.0% |
6 Months | 36.77% | 10.2% | 0.0% |
1 Year | -72.0% | 19.6% | 0.0% |
3 Years | -96.39% | 16.8% | -23.0% |
Highlights
Market Capitalization | 17.1M |
Book Value | -$0.55 |
Earnings Per Share (EPS) | -13.31 |
PEG Ratio | 0.0 |
Wall Street Target Price | 16.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -1683.61% |
Return On Assets TTM | -134.35% |
Return On Equity TTM | -362.39% |
Revenue TTM | 300.7K |
Revenue Per Share TTM | 0.14 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 81.5K |
EBITDA | -27.2M |
Diluted Eps TTM | -13.31 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -6.81 |
EPS Estimate Next Year | -0.86 |
EPS Estimate Current Quarter | -3.36 |
EPS Estimate Next Quarter | -1.4 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 623.98%
Technicals Summary
Sell
Neutral
Buy
Geovax Labs Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Geovax Labs Inc | -22.34% | 36.77% | -72.0% | -96.39% | -95.19% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Geovax Labs Inc | NA | NA | 0.0 | -6.81 | -3.62 | -1.34 | NA | -0.55 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Geovax Labs Inc | Buy | $17.1M | -95.19% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Geovax Labs Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 155.4%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 141.2%
Institutional Holdings
Armistice Capital, LLC
0.94%Bank of America Corp
0.53%BlackRock Inc
0.32%Vanguard Group Inc
0.23%Geode Capital Management, LLC
0.16%Tower Research Capital LLC
0.09%
Company Information
geovax labs, inc., (otcqb: govx) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our modified vaccinia ankara - virus-like particle (mva-vlp) vaccine platform. our development programs are focused on preventive vaccines against hiv, zika virus, hemorrhagic fever viruses (ebola, sudan, marburg, and lassa), and malaria, as well as therapeutic vaccines for chronic hepatitis b infections and cancers. our mva-vlp platform supports in vivo production of non-infectious vlps from the cells of the very person receiving the vaccine, mimicking a natural infection, and stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. for more information, visit www.geovax.com.
Organization | Geovax Labs Inc |
Employees | 17 |
CEO | Mr. David Alan Dodd |
Industry | Biotechnology |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$2.21
+4.25%
Invesco Bulletshares 2025 Hi
$2.21
+4.25%
Schwab International Dividend Equity Etf
$2.21
+4.25%
Blockchain Coinvestors Acquisition Corp.
$2.21
+4.25%
Allgiant Travel Company
$2.21
+4.25%
Rogers Corp
$2.21
+4.25%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$2.21
+4.25%
Iheartmedia
$2.21
+4.25%
Lightpath Technologies Inc
$2.21
+4.25%